Novo Nordisk's liraglutide, currently approved for adult obesity management, is being evaluated for pediatric use in children aged 6 to below 12 years. The trial aims to address a significant unmet need in the pediatric obesity market, which is growing due to rising obesity rates among children. If successful, liraglutide could capture a substantial share of this market, particularly as there are limited effective pharmacological options for this age group. Competitive landscape analysis indicates that while there are other obesity treatments, few are specifically targeted at children, potentially positioning liraglutide as a first-line therapy. Diligence implications include monitoring regulatory pathways and potential market access challenges, as pediatric formulations often face additional scrutiny.